

# Maternal molecular hydrogen administration on lipopolysaccharide-induced mouse fetal brain injury

Tomoko Nakano,<sup>1</sup> Tomomi Kotani,<sup>1,\*</sup> Yukio Mano,<sup>1</sup> Hiroyuki Tsuda,<sup>1</sup> Kenji Imai,<sup>1</sup> Takafumi Ushida,<sup>1</sup> Hua Li,<sup>1</sup> Rika Miki,<sup>2</sup> Seiji Sumigama,<sup>1</sup> Yoshiaki Sato,<sup>3</sup> Akira Iwase,<sup>1</sup> Akihiro Hirakawa,<sup>4</sup> Masato Asai,<sup>5</sup> Shinya Toyokuni,<sup>6</sup> and Fumitaka Kikkawa<sup>1</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, <sup>2</sup>Bio-database Institute of Reproductive and Developmental Medicine, <sup>4</sup>Biostatistics Section, Center for Advanced Medicine and Clinical Research Cancer, <sup>5</sup>Department of Pathology and <sup>6</sup>Pathology and Biological Responses, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

<sup>3</sup>Division of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan

(Received 4 August, 2015; Accepted 11 August, 2015; Published online 21 October, 2015)

Fetal brain injury is often related to prenatal inflammation; however, there is a lack of effective therapy. Recently, molecular hydrogen (H<sub>2</sub>), a specific antioxidant to hydroxyl radical and peroxynitrite, has been reported to have anti-inflammatory properties. The aim of this study was to investigate whether maternal H<sub>2</sub> administration could protect the fetal brain against inflammation. Pregnant C3H/HeN mice received an intraperitoneal injection of lipopolysaccharide (LPS) on gestational day 15.5 and were provided with H<sub>2</sub> water for 24 h prior to LPS injection. Pup brain samples were collected on gestational day 16.5, and the levels of apoptosis and oxidative damage were evaluated using immunohistochemistry. Interleukin-6 (IL-6) levels were examined using real-time PCR. The levels of apoptosis and oxidative damage, as well as the levels of IL-6 mRNA, increased significantly when the mother was injected with LPS than that in the control group. However, these levels were significantly reduced when H<sub>2</sub> was administered prior to the LPS-injection. Our results suggest that LPS-induced apoptosis, oxidative damage and inflammation in the fetal brain were ameliorated by maternal H<sub>2</sub> administration. Antenatal H<sub>2</sub> administration might protect the premature brain against maternal inflammation.

**Key Words:** molecular hydrogen, premature infant, anti-oxidant, anti-inflammation, brain injury

Worldwide, the number of preterm birth is increasing. Currently, up to 11.1% of all infants are born prematurely.<sup>(1)</sup> Although the survival rates of these infants continuous to improve, the frequency of morbidities including brain injury remains high.<sup>(2)</sup> Perinatal brain injury can result in neonatal mortality or a long-term neurologic disability,<sup>(3)</sup> and the total number of children with lifelong health problems rises in developed countries.<sup>(2)</sup> Therefore, it is imperative to develop new strategies that can aid in reducing the number of premature births and perinatal brain injury. The poor prognosis has been reported to be related with prenatal exposure to inflammation.<sup>(4,5)</sup> Accumulating evidence suggests that elevation of interleukin-6 (IL-6) in the amniotic fluid is a marker of chorioamnionitis and indicates a poor prognosis for neonates.<sup>(6–9)</sup> Intrauterine infection or inflammation also causes preterm birth<sup>(10)</sup> and prematurity is a causative factor of neonatal brain injury.<sup>(11)</sup> These data suggest that prenatal administration of anti-inflammatory agents could be an effective therapeutic approach.<sup>(3)</sup>

Molecular hydrogen (H<sub>2</sub>) is a specific scavenger of hydroxyl radicals and peroxynitrite, and has been used as an innovated

therapy in adult brain injury.<sup>(12–14)</sup> Several studies have reported the therapeutic effects of H<sub>2</sub> in oxidative stress-related diseases, including Parkinson's disease, and Diabetes Mellitus.<sup>(15)</sup> Several clinical trials with H<sub>2</sub> have been initiated and so far, no side effects have been reported.<sup>(14)</sup> Recently, we found that maternal administration of H<sub>2</sub> affects fetal cerebral damage in an ischemia-reperfusion model.<sup>(16)</sup> We demonstrated that maternal administration of H<sub>2</sub> increased H<sub>2</sub> concentrations in the fetal brain, which resulted in the reduction of oxidative damage and apoptosis in the hippocampus.<sup>(16)</sup>

From these findings, we hypothesized that maternal administration of H<sub>2</sub> might also be effective at reducing fetal brain damage caused by intrauterine inflammation. Thus, we investigated the effects of maternal H<sub>2</sub> administration on the fetal mouse brain by evaluating apoptosis, oxidative stress, and the level of IL-6.

## Materials and Methods

**Animals and treatments.** The experimental procedures in this study were approved by the Animal experiment Committee of the Nagoya University Graduate School of Medicine (approval number: 25096). C3H/HeN mouse were purchased from Charles River Laboratories (Yokohama, Japan) and housed in plastic cages. All mice were maintained on a 12 h light/12 h dark lighting schedule (lights on at 9:00 am, off at 9:00 pm), and subjected to a standard chow diet (CE-2) and water *ad libitum*. As previously reported, virgin female mice were mated with fertile males of the same strain.<sup>(17)</sup> The timing of pregnancy was determined by visual inspection of the vaginal plug, which was defined as day 0.5 of pregnancy.<sup>(17)</sup> Normal term labor occurs on day 19.5 of gestation (G19.5), under our animal facility conditions. Approximately 50%-saturated hydrogen water (H<sub>2</sub> water) was a kind gift from Blue Mercury, Inc. (Tokyo, Japan). The H<sub>2</sub> water was exchanged every 24 h to maintain the concentration above 0.4 mM, as previously reported.<sup>(16)</sup> The mice were assigned randomly to three groups: a control group that was intraperitoneally (i.p.) injected with vehicle (0.5 ml of sterile PBS) on G15.5, a lipopolysaccharide (LPS) group receiving 5 µg of LPS (*Escherichia coli* LPS, serotype 055:B5; Sigma-Aldrich Japan, Tokyo, Japan) in 0.5 ml of sterile PBS by i.p. on G15.5, and an H<sub>2</sub> water + LPS group, that in addition to the LPS i.p. injection on G15.5, received H<sub>2</sub> water, starting from one day prior to LPS i.p. (on G14.5), until

\*To whom correspondence should be addressed.  
E-mail: itoto@med.nagoya-u.ac.jp


the end of the experiment (day 16.5 of pregnancy).

Twenty-four hours after LPS or PBS i.p. (on G16.5), the brain tissue from the fetuses were collected ( $n = 10$  for each group).

**Measurement of IL-6 in amniotic fluid.** The amniotic fluid from all sacs in a mother (6 mothers for each group) were aspirated by syringe and assembled on G16.5. IL-6 levels were measured by ELISA (Quantikine® ELISA, M6000B; R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. The experiments were performed in duplicate.


**Quantitative real time polymerase chain reaction (qRT-PCR).** The fetal brains collected on G16.5 were grinded using a Power Masher (Nippi, Tokyo, Japan) and total RNA was isolated using the RNeasy Mini Kit (Qiagen Inc., Tokyo, Japan) following the manufacturer's directions. Complementary DNAs were prepared with a first strand cDNA synthesis kit (Rever Tra Ace- $\alpha$ ; Toyobo Co., Ltd, Osaka, Japan), according to the manufacturer's directions using a MyCycler™ thermal cycler (BIORAD, Hercules, CA). Subsequently, qRT-PCR was performed using the Thermal Cycler Dice (Takara Bio Inc., Tokyo, Japan) and SYBR II Premix Ex Taq (Takara Bio Inc.) according to the manufacturer's directions. Data were normalized based on the expression of the house-keeping gene beta-actin. The primer sequences (NIPPON EGT CO., LTD., Toyama, Japan) were as follows: mouse  $\beta$ -actin forward: 5'-CGTGGGCCGCCCTAGGCACCA-3' and reverse: 5'-ACACGCAGCTCATTGTA-3'; mouse IL-6 forward: 5'-ACAAC-CACGGCCTTCCCTAC-3' and reverse: 5'-TCCACGATTTCCC-AGAGAACA-3'.

**Immunohistochemistry.** Immunohistochemistry was performed as previously reported.<sup>(18)</sup> Briefly, formalin-fixed, paraffin-embedded tissue sections were cut at a thickness of 4  $\mu$ m. For heat-induced epitope retrieval, deparaffinized sections placed in 1 mM citrate buffer (pH 6.0) were heated for 20 min each at 90°C and 750 W using an H2500 microwave oven. Staining was performed using Vector® M.O.M™ Immunodetection Kit Basic (Vector Laboratories, Inc., Burlingame, CA) to detect specifically to localize mouse primary antibodies on mouse tissues, and VECTASTAIN Elite ABC Reagent (Vector Laboratories, Inc.) for chromogenic detection, based on the manufacturer's instructions. Anti-mouse monoclonal antibody against 8-oxo-7,8-dihydro-2'



**Fig. 1.** IL-6 proteins in the amniotic fluid. The results are expressed as the means  $\pm$  SEM ( $n = 6$ ). IL-6 in the amniotic fluid showed a tendency to decrease in the H<sub>2</sub> water + LPS group compared with that observed in the LPS group. The  $p$  values were calculated according to the Student's  $t$  test (Cont vs LPS) and the Mann-Whitney test (LPS vs H<sub>2</sub> water + LPS and Cont vs H<sub>2</sub> water + LPS, respectively). Cont = PBS i.p. control group, LPS = LPS i.p. injected group, H<sub>2</sub> water + LPS = maternal H<sub>2</sub> water intake prior to LPS i.p. injection.

deoxyguanosine (8-OHdG) (Nikken Seil Co., Ltd., Shizuoka, Japan) was used at a 1:50 dilution for a primary antibody. Finally, the slides were counterstained with Meyer's hematoxylin. For the quantification of 8-OHdG immunostaining, the intensity was evaluated as intensity score (IS), previously reported.<sup>(19)</sup> Briefly, two examiners determined IS in three segments per slide in a double blinded manner, based on a 4-point system: 0, 1, 2, and 3 (for none, light, medium, or dark staining, respectively). Apoptotic cells of fetal brain were identified using the *In Situ* Cell Death Detection Kit, Fluorescein (Roche Applied Science, Mannheim, Germany), according to the manufacturer's instructions. The number of TUNEL positive cells were determined at




**Fig. 2.** The effect of H<sub>2</sub> and LPS on fetuses. Representative photographs of fetuses from gestational day 16.5, 24 h after the injection of LPS. Arrows indicate decrease in cerebral irrigation in the fetuses of the LPS group. Cerebral irrigation was improved in the H<sub>2</sub> water + LPS group. Cont = PBS i.p. control group, LPS = LPS i.p. injected group, H<sub>2</sub> water + LPS = maternal H<sub>2</sub> water intake prior to LPS i.p. injection.

×400 magnifications in three segments per slide by two examiners independently.

**Statistical analysis.** Statistical analyses were performed using the SPSS software package ver. 22 (SPSS Inc., Chicago, IL). The distribution and variance were examined using the Shapiro-Wilk

test. Student's *t* test and The Mann-Whitney test were performed to assess variables with normal and non-normal distributions, respectively. Differences between groups were considered significant at a *p* value of <0.05.




**Fig. 3.** (A) Representative data for TUNEL staining (left columns) and immunohistochemical staining for 8-OHdG (right columns) of fetal brain tissue. Number of TUNEL positive cells and intensity score of 8-OHdG were significantly increased in the LPS group compared with the control group, but these induction was completely attenuated in the H<sub>2</sub> water + LPS group. The original magnification is 40× (scale bar = 200 μm) in the left side and 400× (scale bar = 50 μm) in the images on the right side, respectively. The arrows indicate cells positive for TUNEL, an apoptotic marker, or 8-OHdG, a marker for oxidative damage on DNA. (B) The TUNEL positive cells were quantified and presented as the mean ± SEM. *P* values were calculated according to the Mann-Whitney test. (C) 8-OHdG staining was scored as intensity score (IS) and is presented as the mean ± SEM. The *p* values were calculated according to the Mann-Whitney test (Cont vs LPS and Cont vs H<sub>2</sub> water + LPS) or the Student's *t* test (LPS vs H<sub>2</sub> water + LPS). Cont = PBS i.p. control group, LPS = LPS i.p. injected group, H<sub>2</sub> water + LPS = maternal H<sub>2</sub> water intake prior to LPS i.p. injection.

## Results

**H<sub>2</sub> water reduced LPS-induced intra-amniotic inflammation.** The concentration of IL-6 in the amniotic fluid of the LPS group showed an approximately 10-fold increase compared to the control group (Fig. 1,  $p = 0.025$ ). This induction was partially decreased in the H<sub>2</sub> water + LPS group compared to the LPS group, but this difference was found not to be statistically significant (Fig. 1,  $p = 0.078$ ).

**H<sub>2</sub> water alleviated cerebral irrigation.** Representative images of the macroscopic findings of fetuses from three groups 24 h after PBS or LPS i.p. injection are shown in Fig. 1. The reduction of cerebral irrigation with partial melting limbs was observed in 45.8% of the fetuses in the LPS group (Fig. 2, middle panel). However, these read-outs were improved in the H<sub>2</sub> water + LPS group (Fig. 2, bottom panel), and the population of fetuses with those findings in the H<sub>2</sub> water + LPS group was reduced to only 26.1%.

**H<sub>2</sub> water relieved LPS-induced inflammation, oxidative stress and apoptosis in fetal brains.** To evaluate the effect of H<sub>2</sub> on the fetal brain damage induced by maternal administration of LPS, the number of apoptotic cells was measured in fetal brain specimens of the three groups. The number of TUNEL-positive cells in the LPS group was significantly increased, in comparison to the control group (Fig. 3A and B,  $p < 0.001$ ), whereas the number of TUNEL-positive cells in the H<sub>2</sub> water + LPS group was completely restored to the same level as that of the control group (Fig. 3A and B,  $p = 0.001$ ). To investigate whether LPS induced oxidative stress in the fetal brain, anti-8-OHdG immunostaining was performed. The intensity score calculated in the LPS group was significantly increased beyond that in the Control group (Fig. 3A and C,  $p = 0.004$ ), but that detected in the H<sub>2</sub> water + LPS group was significantly reduced, back to the same level as that in the control group (Fig. 3A and C,  $p < 0.001$ ). The expression of IL-6 mRNA in whole fetal brains from the LPS group was significantly increased, compared with the levels found in the control group (Fig. 4,  $p = 0.003$ ). Again, IL-6 mRNA levels were significantly reduced in the H<sub>2</sub> water + LPS group (Fig. 4,  $p = 0.041$ ), and there was no significant difference in IL-6 mRNA



**Fig. 4.** IL-6 mRNA expression in the fetal brain was significantly increased in the LPS group, compared with that detected in the control group. This induction was completely decreased in the H<sub>2</sub> water + LPS group. The data were normalized to the expression of beta-actin and are presented as the mean  $\pm$  SEM.  $P$  values were calculated according to the Mann-Whitney test. Cont = PBS i.p. control group, LPS = LPS i.p. injected group, H<sub>2</sub> water + LPS = maternal H<sub>2</sub> water intake prior to LPS i.p. injection.

levels between the control group and the H<sub>2</sub> water + LPS group. TNF- $\alpha$  and IL-1 $\beta$  expression were not detected in the control or the LPS group (data not shown).

## Discussion

In the present study, we have demonstrated that maternal administration of H<sub>2</sub> has a suppressive effect on fetal brain injury caused by intrauterine inflammation. Maternal intraperitoneal injection of LPS in animals has previously been used to model maternal inflammation-induced perinatal brain injury.<sup>(20,21)</sup> Using this model, we found that the levels of IL-6 in the amniotic fluid were elevated, consistent with a previous report.<sup>(21)</sup> Clinical evidence has demonstrated that the elevated levels of IL-6 in the amniotic fluid are a marker of intrauterine infection,<sup>(22)</sup> and a predictor of preterm birth<sup>(22)</sup> and histological chorioamnionitis.<sup>(23)</sup> Elevated IL-6 levels are associated with adverse perinatal outcomes and fetal brain injury.<sup>(24,25)</sup> In this study, we observed a reduction in cerebral irrigation in the fetus, similar to another report.<sup>(17)</sup> Moreover, immunohistochemical analysis of the fetal brain revealed that the number of apoptotic cells was markedly increased, which was accompanied with an increased expression of 8-OHdG, a marker of DNA oxidative damage, and IL-6, an inflammation marker. Thus, LPS-induced intrauterine inflammation caused reduced blood flow, increased oxidative stress and inflammation in the fetal brain of the animals, eventually leading to fetal brain damage. It mimics the pathological state of the neonatal brain after injury caused by chorioamnionitis. All of these symptoms were attenuated by maternal H<sub>2</sub> administration prior to LPS injection.

H<sub>2</sub> was initially reported to act as an antioxidant, preventing brain injury by selectively targeting cytotoxic oxygen radicals.<sup>(12)</sup> H<sub>2</sub> has a rapid rate of diffusion and effectively reaches the nucleus, where it can protect nuclear DNA from oxidative damage.<sup>(12)</sup> Several researchers also observed that H<sub>2</sub> reduces oxidative DNA damage in brain tissues, indicating its potential as a neuroprotective potential.<sup>(26-28)</sup> In addition, H<sub>2</sub> can penetrate the blood-brain barrier, an important advantage of using H<sub>2</sub> over other neuroprotective drugs.<sup>(16)</sup> We have previously confirmed that maternal H<sub>2</sub> administration increases the H<sub>2</sub> concentrations in the fetal brains.<sup>(16,18)</sup> Thus, it could be postulated that H<sub>2</sub> administered to the mother could pass through the blood-brain barrier and protect fetal brain cells against oxidative stress or inflammation. Indeed, it has been reported that H<sub>2</sub> has an anti-inflammatory effect.<sup>(14)</sup> H<sub>2</sub> reduced the mRNA expression of pro-inflammatory cytokines including IL-6 in an adult mouse model of LPS-induced neuroinflammation.<sup>(29)</sup> Other studies reported that H<sub>2</sub> improves memory function via suppression of IL-6 expression in brain tissues in a rat model of Alzheimer's disease.<sup>(30)</sup> Based on those results, it can be concluded that H<sub>2</sub> suppresses oxidative DNA damage and the expression of IL-6 in the adult brain. Moreover, our results now show that these effects of H<sub>2</sub> are also detected in the fetal brain after maternal H<sub>2</sub> administration. The effects of H<sub>2</sub> water administration were milder in the amniotic fluid than in the fetal brain. This might be due to the fact that maternal H<sub>2</sub> water administration leads to an increase in H<sub>2</sub> concentration in the fetal brain, but not in the amniotic fluid.<sup>(16)</sup> We speculate that the effects of H<sub>2</sub> on the fetal brain tissue are mainly due to its direct action in the fetal brain tissue, but they may be partially explained by anti-inflammatory effect on the intrauterine inflammation itself.

The present study has several limitations. Only IL-6 was found to be increased in the LPS group in this study, but other pro-inflammatory cytokines such as TNF- $\alpha$  and IL-1 $\beta$ , which are also important in the pathogenesis of brain injury resulting from chorioamnionitis or fetal inflammatory response syndrome, were not detected.<sup>(4)</sup> It has previously been reported that these cytokines are increased in the fetal brain after intrauterine injection of LPS.<sup>(31,32)</sup> and the effect of H<sub>2</sub> on the expression of these cytokines

remains to be established and confirmed in the other strains. Furthermore, the H<sub>2</sub> administration protocol should be revised for clinical research. The timing to start therapy is important for efficacy.<sup>(33)</sup> After obtaining promising results in this proof-of-principal study, we will now proceed with a further evaluation of H<sub>2</sub> dosages suitable for clinical use.

In conclusion, maternal administration of H<sub>2</sub> water prevents fetal brain damage caused by intrauterine inflammation. Prophylactic use of H<sub>2</sub> might improve the neurological prognosis of premature neonates delivered from mothers suffering from intrauterine inflammation.

## Acknowledgments

We acknowledge Mrs. Kaori Ushida (Department of Pathology, Nagoya University Graduate School of Medicine) for her valuable

technical support. 50%-saturated hydrogen water were kind gifts from Blue Mercury, Inc. (Tokyo, Japan). This work was supported by JSPS KAKENHI, Grant Number 26462484.

## Conflict of Interest

The authors have no conflicts of interest to declare in association with this study. The authors are responsible for the content and writing of the paper.

## Abbreviations

8-OHdG	8-hydroxy-2'-deoxyguanosine
PBS	phosphate buffered saline
LPS	lipopolysaccharide

## References

- 1 Blencowe H, Cousens S, Oestergaard MZ, *et al.* National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. *Lancet* 2012; **379**: 2162–2172.
- 2 Costeloe KL, Hennessy EM, Haider S, Stacey F, Marlow N, Draper ES. Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies). *BMJ* 2012; **345**: e7976.
- 3 Salmeen KE, Jelin AC, Thiet MP. Perinatal neuroprotection. *F1000Prime Rep* 2014; **6**: 6.
- 4 Chau V, McFadden DE, Poskitt KJ, Miller SP. Chorioamnionitis in the pathogenesis of brain injury in preterm infants. *Clin Perinatol* 2014; **41**: 83–103.
- 5 Chau V, Poskitt KJ, McFadden DE, *et al.* Effect of chorioamnionitis on brain development and injury in premature newborns. *Ann Neurol* 2009; **66**: 155–164.
- 6 Girard S, Kadhim H, Roy M, *et al.* Role of perinatal inflammation in cerebral palsy. *Pediatr Neurol* 2009; **40**: 168–174.
- 7 Hagberg H, Gressens P, Mallard C. Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults. *Ann Neurol* 2012; **71**: 444–457.
- 8 Murthy V, Kennea NL. Antenatal infection/inflammation and fetal tissue injury. *Best Pract Res Clin Obstet Gynaecol* 2007; **21**: 479–489.
- 9 Normann E, Lacaze-Masmonteil T, Eaton F, Schwendimann L, Gressens P, Thébaud B. A novel mouse model of Ureaplasma-induced perinatal inflammation: effects on lung and brain injury. *Pediatr Res* 2009; **65**: 430–436.
- 10 Burdet J, Rubio AP, Salazar AI, Ribeiro ML, Ibarra C, Franchi AM. Inflammation, infection and preterm birth. *Curr Pharm Des* 2014; **20**: 4741–4748.
- 11 Hagberg H, Mallard C, Jacobsson B. Role of cytokines in preterm labour and brain injury. *BJOG* 2005; **112 Suppl 1**: 16–18.
- 12 Ohsawa I, Ishikawa M, Takahashi K, *et al.* Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. *Nat Med* 2007; **13**: 688–694.
- 13 Ohta S. Recent progress toward hydrogen medicine: potential of molecular hydrogen for preventive and therapeutic applications. *Curr Pharm Des* 2011; **17**: 2241–2252.
- 14 Ohta S. Molecular hydrogen as a novel antioxidant: overview of the advantages of hydrogen for medical applications. *Methods Enzymol* 2015; **555**: 289–317.
- 15 Ohno K, Ito M, Ichihara M, Ito M. Molecular hydrogen as an emerging therapeutic medical gas for neurodegenerative and other diseases. *Oxid Med Cell Longev* 2012; **2012**: 353152.
- 16 Mano Y, Kotani T, Ito M, *et al.* Maternal molecular hydrogen administration ameliorates rat fetal hippocampal damage caused by in utero ischemia-reperfusion. *Free Radic Biol Med* 2014; **69**: 324–330.
- 17 Domínguez Rubio AP, Sordelli MS, Salazar AI, *et al.* Melatonin prevents experimental preterm labor and increases offspring survival. *J Pineal Res* 2014; **56**: 154–162.
- 18 Hattori Y, Kotani T, Tsuda H, *et al.* Maternal molecular hydrogen treatment attenuates lipopolysaccharide-induced rat fetal lung injury. *Free Radic Res* 2015; **49**: 1026–1037.
- 19 Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. *Mod Pathol* 1998; **11**: 155–168.
- 20 Rose KM, Parmar MS, Cavanaugh JE. Dietary supplementation with resveratrol protects against striatal dopaminergic deficits produced by in utero LPS exposure. *Brain Res* 2014; **1573**: 37–43.
- 21 Awad N, Khatib N, Ginsberg Y, *et al.* N-acetyl-cysteine (NAC) attenuates LPS-induced maternal and amniotic fluid oxidative stress and inflammatory responses in the preterm gestation. *Am J Obstet Gynecol* 2011; **204**: 450.e415–420.
- 22 Romero R, Avila C, Santhanam U, Sehgal PB. Amniotic fluid interleukin 6 in preterm labor. Association with infection. *J Clin Invest* 1990; **85**: 1392–1400.
- 23 Kacerovsky M, Musilova I, Hornychova H, *et al.* Bedside assessment of amniotic fluid interleukin-6 in preterm prelabor rupture of membranes. *Am J Obstet Gynecol* 2014; **211**: 385.e1–9.
- 24 Combs CA, Gravett M, Garite TJ, *et al.* Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. *Am J Obstet Gynecol* 2014; **210**: 125.e1–125.e15.
- 25 Rees S, Harding R, Walker D. The biological basis of injury and neuroprotection in the fetal and neonatal brain. *Int J Dev Neurosci* 2011; **29**: 551–563.
- 26 Hayashida K, Sano M, Kamimura N, *et al.* H<sub>2</sub> gas improves functional outcome after cardiac arrest to an extent comparable to therapeutic hypothermia in a rat model. *J Am Heart Assoc* 2012; **1**: e003459.
- 27 Nagatani K, Takeuchi S, Kobayashi H, *et al.* The effect of hydrogen gas on a mouse bilateral common carotid artery occlusion. *Acta Neurochir Suppl* 2013; **118**: 61–63.
- 28 Shen L, Wang J, Liu K, *et al.* Hydrogen-rich saline is cerebroprotective in a rat model of deep hypothermic circulatory arrest. *Neurochem Res* 2011; **36**: 1501–1511.
- 29 Spulber S, Edoff K, Hong L, Morisawa S, Shirahata S, Ceccatelli S. Molecular hydrogen reduces LPS-induced neuroinflammation and promotes recovery from sickness behaviour in mice. *Plos One* 2012; **7**: e42078.
- 30 Li J, Wang C, Zhang JH, Cai JM, Cao YP, Sun XJ. Hydrogen-rich saline improves memory function in a rat model of amyloid-beta-induced Alzheimer's disease by reduction of oxidative stress. *Brain Res* 2010; **1328**: 152–161.
- 31 Burd I, Bentz AI, Chai J, *et al.* Inflammation-induced preterm birth alters neuronal morphology in the mouse fetal brain. *J Neurosci Res* 2010; **88**: 1872–1881.
- 32 Chang EY, Zhang J, Sullivan S, Newman R, Singh I. N-acetylcysteine attenuates the maternal and fetal proinflammatory response to intrauterine LPS injection in an animal model for preterm birth and brain injury. *J Matern Fetal Neonatal Med* 2011; **24**: 732–740.
- 33 Shichiri M. The role of lipid peroxidation in neurological disorders. *J Clin Biochem Nutr* 2014; **54**: 151–160.